<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03971032</url>
  </required_header>
  <id_info>
    <org_study_id>HYMC-0098-18</org_study_id>
    <nct_id>NCT03971032</nct_id>
  </id_info>
  <brief_title>An In-vitro Real-time System Based on Tissue Smears to Identify Malignancy During Hysteroscopic Procedure</brief_title>
  <official_title>A Development of an In-vitro Real-time System Based on Tissue Smears to Identify Malignancy During Hysteroscopic Procedure Using FTIR-ATR Spectroscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hillel Yaffe Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hillel Yaffe Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the current study is to develop a near real-time system using infrared
      spectroscopy, that will evaluate the histological specimen that was removed from the uterine
      cavity during the hysteroscopy.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 31, 2019</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison of infrared spectroscopy with routine histopathology</measure>
    <time_frame>3 years</time_frame>
    <description>Tissue smears that have undergone infrared spectroscopy during hysteroscopy will have a different spectral absorption than healthy tissue, thus indicating malignancy. These results will be compared to the results of routine histopathology to determine accuracy of spectroscopy to indicate malignancy.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Uterine Cervical Neoplasm</condition>
  <condition>Uterine Neoplasms</condition>
  <arm_group>
    <arm_group_label>Women undergoing hysteroscopy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Women presenting with abnormal bleeding, abnormal cervical or uterine findings who have consented to undergo hysteroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Hysteroscopy</intervention_name>
    <description>Diagnostic procedure</description>
    <arm_group_label>Women undergoing hysteroscopy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Infrared Spectroscopy</intervention_name>
    <description>This device uses spectral absorption of the tissue taken during hysteroscopy to determine immediate diagnosis of malignancy</description>
    <arm_group_label>Women undergoing hysteroscopy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing hysteroscopy

        Exclusion Criteria:

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ilan Bruchim, MD</last_name>
    <phone>972-4-7744335</phone>
    <email>ilanb@hy.health.gov.il</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hillel Yaffe Medical Center</name>
      <address>
        <city>Hadera</city>
        <zip>38100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Ilan Bruchim, MD</last_name>
      <email>ilanb@hy.health.gov.il</email>
    </contact>
    <investigator>
      <last_name>Ilan Bruchim, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>May 1, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 3, 2019</study_first_posted>
  <last_update_submitted>December 3, 2019</last_update_submitted>
  <last_update_submitted_qc>December 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
    <mesh_term>Uterine Neoplasms</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

